avelumab,cabozantinib
pfizer,merck,exelixis
['maincav']
 excellent discussion indeed by shilpa! maincav will be a beautiful study to further our ability to extend clinical benefits for the cis eligible and responsive pts (still no curable treatment yet!) 
Physician Scientist, Cancer Immunologist, opinions are my own